Induced Changes in Ventilatory Responsiveness and Altitude Exposure

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Effects of High Altitude, Hypoxia, Inadequate or Impaired Breathing Pattern or Ventilation, Abnormal Blood Oxygen Pressure

In brief

The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol overdoses. Other forms of ACCY are also sold over-the-counter as nutritional supplements. In this study, the FDA-approved form of ACCY will be used "off-label" (meaning in a way not approved by the FDA). This study is being conducted by researchers from the United States Army Research Institute of Environmental Medicine (USARIEM). The study will take place in the Altitude Chamber located in the basement of USARIEM. A total of approximately 30 volunteers (men and women, military and civilians) will take part in the study. They can expect to be in the study for a minimum of a few hours each day for two weeks. The investigators hypothesize that ACCY will improve ventilation and oxygenation while at altitude.

Key facts

Study ID
NCT01241513
Run by
United States Army Research Institute of Environmental Medicine
People needed
21
Starts
2010-11-01
Expected to finish
2013-02-28
Last updated by the study team
2020-04-30

Who can join

Age: 18 and older, up to 39. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.